CAR-T cell therapy: a breakthrough in the fight against cancer

CAR-T cell therapy (Chimeric Antigen Receptor T-cell Therapy) is an adoptive cell therapy that uses genetically modified T-lymphocytes from the patient. These cells are equipped with chimeric antigen receptors (CARs), which enable them to recognize and destroy cancer cells. The core principle of the therapy involves “reprogramming” the patient’s immune system to overcome the mechanisms that help cancer cells evade attack.

The treatment process includes several stages:

1. Cell collection: immune cells are collected from the patient’s blood (apheresis).
2. Genetic modification: the selected cells are sent to a specialized laboratory where they undergo gene engineering. The immune cells are trained to recognize and destroy cancer cells.
3. Patient preparation: before the modified cells are infused, the patient undergoes a short course of chemotherapy to weaken the immune system and improve the cells’ survival rate.
4. Cell infusion: the genetically modified T-lymphocytes are intravenously infused into the patient. The procedure takes less than an hour.
5. Inpatient monitoring: the patient remains under observation for 10–15 days to monitor for potential side effects.

The Tel Aviv medical center, also known as Ichilov Hospital, became the first facility outside of the United States to implement this therapy. The hematology department of Ichilov has unique expertise in treating leukemia, lymphoma, and other blood malignancies. The department is led by professor Irit Avivi, who, along with her team, ensures a personalized approach to each patient and effective management of therapy side effects.

In Israel, CAR-T cell therapy is used for the following conditions:

• Diffuse large B-cell lymphoma: the therapy is indicated for middle-aged and older patients whose previous treatments were ineffective.
• B-cell acute lymphoblastic leukemia: the treatment is intended for young patients under 25 years of age suffering from relapses of the disease.

The hematology department of Ichilov became the first medical center to participate in clinical trials of CAR-T cell therapy outside the United States. This allowed the creation of a robust knowledge base and the necessary technologies for successful treatment. Today, CAR-T cell therapy is performed at a high level by Israeli doctors, adhering to international standards and continually improving their methods. For more detailed information and consultations with specialists regarding treatment, visit this link

CAR-T cell therapy continues to evolve. Key directions include expanding the range of diseases treatable and improving cell modification methods to minimize side effects. The Hematology Department of Ichilov is actively involved in research and implements advanced technologies, making Israel one of the leading countries in oncological therapy.

Israeli specialists use CAR-T cell therapy as an effective tool in the fight against cancer, offering hope to many patients. If you are seeking advanced treatment methods and high-quality medical care, the hematology department of Ichilov is your reliable choice.